Nitish Kumar

Dr. Nitish Kumar

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 January 2025 in International Forum of Allergy & Rhinology
Verified
Journal Article
Closed access
NKNitish Kumar
Nitish Kumar
SJSavannah D. Jett
Savannah D. Jett
PGPedro Lança Gomes
Pedro Lança Gomes
MMMichael J. Marino
Michael J. Marino
AMAmar Miglani
Amar Miglani
Devyani LalDevyani Lal
Devyani Lal

21 November 2025 in International Forum of Allergy & Rhinology
Verified
Journal Article
Open access
NKNitish Kumar
Nitish Kumar
TPTyson Pace
Tyson Pace
PGPedro Lanca Gomes
Pedro Lanca Gomes
MMMichael J. Marino
Michael J. Marino
AMAmar Miglani
Amar Miglani
Devyani LalDevyani Lal
Devyani Lal
Key Points: Contemporary aspirin exacerbated respiratory disorder (AERD) therapy commonly includes aspirin desensitization (55%) and biologics (48%). Aspirin desensitization therapy has higher discontinuation rates than biologics. Patients receiving biologics are younger, and ∼25% of the patients switch to other agents.

11 August 2025 in Laryngoscope Investigative Otolaryngology
Verified
Journal Article
Open access
NKNitish Kumar
Nitish Kumar
PGPedro Lança Gomes
Pedro Lança Gomes
SJSavannah Jett
Savannah Jett
SBStephen F. Bansberg
Stephen F. Bansberg
MMMichael J Marino
Michael J Marino
AMAmar Miglani
Amar Miglani
Objectives: Saddle nose deformity (SND) can be associated with nasal septal perforation (NSP). Both SND and NSP are observed in granulomatosis with polyangiitis (GPA) patients. This study aimed to compare the prevalence and severity of SND in GPA vs. non‐GPA patients with NSP.Methodology: NSP patients who visited tertiary rhinology or facial plastic surgery clinics from January 2010 through December 2023 were grouped into GPA and non‐GPA cohorts. The area of NSP, SND incidence, and SND severity (Daniel and Brenner's classification) were compared between the cohorts.Results: Of 168 patients identified with NSP, 18 had GPA and 150 had non‐GPA diagnoses. Twelve GPA patients and 10 non‐GPA patients had SND. The odds ratio for SND association in GPA patients with NSP vs. non‐GPA patients was 31.3 (95% CI: 9.5–102.9), and 19.4 (95% CI: 4.3–87.7) after controlling for the NSP area. GPA patients with SND had a larger NSP area (median 670 mm2, IQR: 315.5–1061.3) compared to non‐GPA patients with SND (175.3 mm2, 113.1–204.1; p < 0.001). The severity of SND was similar between GPA and the non‐GPA group (p = 0.09). The area of NSP did not predict the severity of SND (p = 0.17).Conclusion: GPA diagnosis was associated with larger NSPs and a higher risk of SND compared to non‐GPA etiologies; however, the severity of saddling did not differ between GPA and non‐GPA etiologies. GPA is an independent risk factor associated with SND irrespective of the size of septal perforation. The NSP area did not predict the severity of SND.Level of Evidence: 4.

14 August 2024 in Sinusitis
Verified
Journal Article
Open access
PDF file
NKNitish Kumar
Nitish Kumar
PGPedro Lanca Gomes
Pedro Lanca Gomes
MMMichael J Marino
Michael J Marino
AMAmar Miglani
Amar Miglani
Devyani LalDevyani Lal
Devyani Lal
Although technical causes of endoscopic sinus surgery (ESS) failure have long been reported, we were curious about the quality of contemporary sinus surgery. The electronic health database of Mayo Clinic, Arizona was scrutinized to identify adult patients with diffuse chronic rhinosinusitis (CRS) who underwent revision ESS between January 2019 and September 2023 with a history of bilateral full-house ESS. Anatomical features on preoperative radiology and intraoperative endoscopy were cataloged: residual uncinate tissue, maxillary antrostomy with a non-incorporated natural os, residual ethmoidal septations (three septations > 3 mm), and inadequate sphenoid osteotomy (os size < 6 mm). Sixty-nine subjects were identified. A deviated nasal septum was present in 53.6%. Residual uncinate tissue was noted in 50.7% of patients associated with missed natural maxillary os in 39.13% of antrostomies. An inadequate os diameter was noted in 63.8% of sphenoidotomies. Significant residual septations were seen in posterior ethmoidal cells in 66.7% and anterior ethmoidal cells in 62.3% of patients. Residual frontoethmoidal cells were noted in 72.4% of patients. Although the extent of ESS must be individualized, a high prevalence of features reflecting suboptimal surgery that could limit the success of ESS was identified. These findings merit further consideration for focused training during residency and continuous professional development activities.

5 February 2026 in Facial Plastic Surgery & Aesthetic Medicine
Verified
Journal Article
Closed access
NKNitish Kumar
Nitish Kumar
TPTyson Pace
Tyson Pace
PGPedro Lança Gomes
Pedro Lança Gomes
SBStephen F. Bansberg
Stephen F. Bansberg
MMMichael J. Marino
Michael J. Marino
AMAmar Miglani
Amar Miglani

10 February 2026 in Laryngoscope Investigative Otolaryngology
Verified
Journal Article
Open access
NKNitish Kumar
Nitish Kumar
PGPedro Lanca Gomes
Pedro Lanca Gomes
GJGaurav Jategaonkar
Gaurav Jategaonkar
MMMichael J Marino
Michael J Marino
AMAmar Miglani
Amar Miglani
Devyani LalDevyani Lal
Devyani Lal
Objectives: We evaluated the impact of teprotumumab therapy ( TT ) introduction on orbital decompression ( OD ) utilization for thyroid eye disease ( TED ) and compared rates of significant exophthalmos reduction ( SER ) and diplopia between TT and OD . Methods: Newly diagnosed TED patients treated pre (2015–2020) and post teprotumumab (2020–2025) FDA approval were identified from the EHR . Utilization trends, diplopia rates, and immediate (≤ 6 weeks post‐intervention) and long‐term follow‐up SER (≥ 2 mm reduction) were studied. Results: Of 406 TED patients, 53 (36.8%) underwent OD in the pre‐ TT cohort ( n = 144). Post‐teprotumumab approval ( n = 262), primary OD was performed in 29 (11.1%), of which 3 (10.3%) were subsequently placed on TT ; primary TT was used in 68/262 (25.9%) with subsequent OD performed in 9 (13.2%). The remaining patients used other treatments (corticosteroids, orbital radiation, rituximab, tocilizumab, etc.). In the overall cohort, immediate SER was achieved in 94.4% of OD versus 83.8% of TT patients ( p = 0.028), with greater median reduction in the OD group (5 vs. 4 mm; p = 0.001). At long‐term follow‐up (median 13 vs. 12 months), SER was sustained in 85.4% of OD and 62.9% of TT patients ( p = 0.042). Pre‐therapy diplopia was more prevalent in TT vs. OD patients (79.4% vs. 59.7%; p = 0.019). New‐onset posttreatment diplopia was higher in the OD group (20.7% vs. 5.9%; p = 0.008). Conclusions: Rates of OD surgery declined following FDA approval of teprotumumab. OD achieved sustained and greater exophthalmos reduction but carried a higher risk of diplopia. Contemporaneous OD indications may have evolved to use in TT‐recalcitrant TED or those in need of urgent decompression. Level of Evidence: 4.